FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384118646> ?p ?o ?g. }

• W4384118646 endingPage "1380" @default.
• W4384118646 startingPage "1374" @default.
• W4384118646 abstract "Abstract Background Guidelines suggest that the serum carbohydrate antigen (CA19-9) level should be used when deciding on neoadjuvant treatment in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (hereafter referred to as pancreatic cancer). In patients with resectable pancreatic cancer, neoadjuvant therapy is advised when the CA19-9 level is ‘markedly elevated’. This study investigated the impact of baseline CA19-9 concentration on the treatment effect of neoadjuvant chemoradiotherapy (CRT) in patients with resectable and borderline resectable pancreatic cancers. Methods In this post hoc analysis, data were obtained from two RCTs that compared neoadjuvant CRT with upfront surgery in patients with resectable and borderline resectable pancreatic cancers. The effect of neoadjuvant treatment on overall survival was compared between patients with a serum CA19-9 level above or below 500 units/ml using the interaction test. Results Of 296 patients, 179 were eligible for analysis, 90 in the neoadjuvant CRT group and 89 in the upfront surgery group. Neoadjuvant CRT was associated with superior overall survival (HR 0.67, 95 per cent c.i. 0.48 to 0.94; P = 0.019). Among 127 patients (70, 9 per cent) with a low CA19-9 level, median overall survival was 23.5 months with neoadjuvant CRT and 16.3 months with upfront surgery (HR 0.63, 0.42 to 0.93). For 52 patients (29 per cent) with a high CA19-9 level, median overall survival was 15.5 months with neoadjuvant CRT and 12.9 months with upfront surgery (HR 0.82, 0.45 to 1.49). The interaction test for CA19-9 level exceeding 500 units/ml on the treatment effect of neoadjuvant CRT was not significant (P = 0.501). Conclusion Baseline serum CA19-9 level defined as either high or low has prognostic value, but was not associated with the treatment effect of neoadjuvant CRT in patients with resectable and borderline resectable pancreatic cancers, in contrast with current guideline advice." @default.
• W4384118646 created "2023-07-14" @default.
• W4384118646 creator A5001294868 @default.
• W4384118646 creator A5002147373 @default.
• W4384118646 creator A5003973735 @default.
• W4384118646 creator A5006641161 @default.
• W4384118646 creator A5015416945 @default.
• W4384118646 creator A5020655761 @default.
• W4384118646 creator A5025416929 @default.
• W4384118646 creator A5031137165 @default.
• W4384118646 creator A5033788401 @default.
• W4384118646 creator A5035117222 @default.
• W4384118646 creator A5039275887 @default.
• W4384118646 creator A5040697057 @default.
• W4384118646 creator A5043399054 @default.
• W4384118646 creator A5046096257 @default.
• W4384118646 creator A5050113054 @default.
• W4384118646 creator A5052876669 @default.
• W4384118646 creator A5062521637 @default.
• W4384118646 creator A5063019493 @default.
• W4384118646 creator A5065157263 @default.
• W4384118646 creator A5071097528 @default.
• W4384118646 creator A5072405531 @default.
• W4384118646 creator A5074957985 @default.
• W4384118646 creator A5077541746 @default.
• W4384118646 creator A5078260564 @default.
• W4384118646 creator A5083297393 @default.
• W4384118646 creator A5087659165 @default.
• W4384118646 creator A5089069968 @default.
• W4384118646 date "2023-07-13" @default.
• W4384118646 modified "2023-09-26" @default.
• W4384118646 title "Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials" @default.
• W4384118646 cites W1825978543 @default.
• W4384118646 cites W2017955572 @default.
• W4384118646 cites W2044211072 @default.
• W4384118646 cites W2075315834 @default.
• W4384118646 cites W2098001605 @default.
• W4384118646 cites W2121289368 @default.
• W4384118646 cites W2131204916 @default.
• W4384118646 cites W2581973599 @default.
• W4384118646 cites W2903623792 @default.
• W4384118646 cites W2912196744 @default.
• W4384118646 cites W2953173394 @default.
• W4384118646 cites W2969945405 @default.
• W4384118646 cites W3008190574 @default.
• W4384118646 cites W3085912351 @default.
• W4384118646 cites W3119005666 @default.
• W4384118646 cites W3197559541 @default.
• W4384118646 cites W3204852424 @default.
• W4384118646 cites W3215936496 @default.
• W4384118646 cites W4226269919 @default.
• W4384118646 doi "https://doi.org/10.1093/bjs/znad210" @default.
• W4384118646 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37440421" @default.
• W4384118646 hasPublicationYear "2023" @default.
• W4384118646 type Work @default.
• W4384118646 citedByCount "0" @default.
• W4384118646 crossrefType "journal-article" @default.
• W4384118646 hasAuthorship W4384118646A5001294868 @default.
• W4384118646 hasAuthorship W4384118646A5002147373 @default.
• W4384118646 hasAuthorship W4384118646A5003973735 @default.
• W4384118646 hasAuthorship W4384118646A5006641161 @default.
• W4384118646 hasAuthorship W4384118646A5015416945 @default.
• W4384118646 hasAuthorship W4384118646A5020655761 @default.
• W4384118646 hasAuthorship W4384118646A5025416929 @default.
• W4384118646 hasAuthorship W4384118646A5031137165 @default.
• W4384118646 hasAuthorship W4384118646A5033788401 @default.
• W4384118646 hasAuthorship W4384118646A5035117222 @default.
• W4384118646 hasAuthorship W4384118646A5039275887 @default.
• W4384118646 hasAuthorship W4384118646A5040697057 @default.
• W4384118646 hasAuthorship W4384118646A5043399054 @default.
• W4384118646 hasAuthorship W4384118646A5046096257 @default.
• W4384118646 hasAuthorship W4384118646A5050113054 @default.
• W4384118646 hasAuthorship W4384118646A5052876669 @default.
• W4384118646 hasAuthorship W4384118646A5062521637 @default.
• W4384118646 hasAuthorship W4384118646A5063019493 @default.
• W4384118646 hasAuthorship W4384118646A5065157263 @default.
• W4384118646 hasAuthorship W4384118646A5071097528 @default.
• W4384118646 hasAuthorship W4384118646A5072405531 @default.
• W4384118646 hasAuthorship W4384118646A5074957985 @default.
• W4384118646 hasAuthorship W4384118646A5077541746 @default.
• W4384118646 hasAuthorship W4384118646A5078260564 @default.
• W4384118646 hasAuthorship W4384118646A5083297393 @default.
• W4384118646 hasAuthorship W4384118646A5087659165 @default.
• W4384118646 hasAuthorship W4384118646A5089069968 @default.
• W4384118646 hasBestOaLocation W43841186461 @default.
• W4384118646 hasConcept C121608353 @default.
• W4384118646 hasConcept C126322002 @default.
• W4384118646 hasConcept C141071460 @default.
• W4384118646 hasConcept C143998085 @default.
• W4384118646 hasConcept C168563851 @default.
• W4384118646 hasConcept C2776694085 @default.
• W4384118646 hasConcept C2778292576 @default.
• W4384118646 hasConcept C2778424827 @default.
• W4384118646 hasConcept C2780210213 @default.
• W4384118646 hasConcept C2781182431 @default.
• W4384118646 hasConcept C530470458 @default.
• W4384118646 hasConcept C67761136 @default.
• W4384118646 hasConcept C71924100 @default.

• next